Evaluation of semi‐quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma

Messina, Julia A.; Cheng, Su Chun; Franc, Benjamin L.; Charron, Martin; Shulkin, Barry L.; To, Bao; Maris, John M.; Yanik, Gregory A.; Hawkins, Randall A.; Matthay, Katherine K.

doi:10.1002/pbc.20777

Cited by 78 publications

(82 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…131 I-MIBG and 18 F-FDG PET/CT scans were assigned scores for bone, and bone marrow lesions according to a previously applied semi-quantitative method [6,7] .…”

Section: Image Analysismentioning

confidence: 99%

“…Semi-quantitative scoring systems have been tested for MIBG, which are correlated with response and, in some cases, event-free survival [7,12] . To document change on PET scans, a standardized uptake value (SUV), is measured for each lesion that can be observed over time to determine response to treatment.…”

Section: Positive Predictive Value: Proportion Of Patients With Positmentioning

confidence: 99%

See 1 more Smart Citation

PET/CT and MIBG scans in diagnosis and management of Neuroblastoma

Fawzy

Moussa²,

Hamouda

et al. 2015

JST

View full text Add to dashboard Cite

Introduction and aim: Several studies report conflicting results about 18 F-FDG/PET and MIBG scans and their diagnostic as well as prognostic significance in children with neuroblastoma. The current study was meant to evaluate both modalities and to compare them in relation to standardized modes of evaluation. Results: FDG/PET showed good results in detecting NB at all sites. FDG/PET also showed a higher sensitivity and specificity, and a better PPV/NPV than MIBG which was not statistically significant. Concordance between paired scans (MIBG, and PET) was found in 55.7% of cases (Kappa=0.001) for primary tumor site, and in 7% for bone and 19.4% for bone marrow. The significance of concordance between both modalities was only demonstrated for metastatic boney lesions. There were 13 patients having stage III neuroblastoma (43.3%) while 17 patients (56.7%) were having stage IV disease. 23 Patients were categorized as high risk (76.7%) while 7 patients (23.3%) were intermediate risk. Both, PET/CT scan and MIBG were more sensitive in detecting disease at stage IV than stage III. Patients and Conclusion:18 F-FDG/PET scan can be used effectively in both diagnosis and management decisions for children with neuroblastoma, it is a good complementary tool especially in detecting bone metastasis, although further clinical trials must agree on definite analytical aspects between both modalities.

show abstract

“…131 I-MIBG and 18 F-FDG PET/CT scans were assigned scores for bone, and bone marrow lesions according to a previously applied semi-quantitative method [6,7] .…”

Section: Image Analysismentioning

confidence: 99%

Section: Positive Predictive Value: Proportion Of Patients With Positmentioning

confidence: 99%

PET/CT and MIBG scans in diagnosis and management of Neuroblastoma

Fawzy

Moussa²,

Hamouda

et al. 2015

JST

View full text Add to dashboard Cite

show abstract

“…Semi-quantitative scoring of scans allows for objective categorization of patients by the extent of disease identified [13]. Measurement of the tumor burden in this way is more than simply an interesting observation, it is clinically useful as it correlates with response and survival, and so can influence the choice of treatment and be of prognostic value.…”

mentioning

confidence: 99%

“…The Curie score, used in COG trials, divides the skeleton into nine segments, adds a tenth for soft tissue, and scores each segment zero to three, making a potential maximum score of 30 [13]. The SIOPEN score, described by Lewington et al [1], divides the skeleton into 12 segments, giving each a score between 0 and 6, making a maximum possible score of 72.…”

mentioning

confidence: 99%

Semi-quantitative scoring of skeletal metastases by 123I-mIBG scintigraphy in high-risk neuroblastoma

Gaze

2017

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

“…Several publications have reported the use of semi-quantitative scoring systems to increase the precision and inter-observer reliability of this test, with success in correlating the results of mIBG scans with early response and event-free survival in some, but not all, reports (Ady et al, 1995;Suc et al, 1996;Frappaz et al, 2000;Hero et al, 2001;Matthay et al, 2003b;Katzenstein et al, 2004). As treatment of stage 4 neuroblastoma continues to be a challenge, with a high rate of relapse in bone and bone marrow, it is essential to have a quantitative and reliable measure of response in bone metastases to test the activity of new therapies for this disease (Messina et al, 2006). The previous international consensus conference on neuroblastoma staging and response criteria recommended mIBG scans as part of the evaluation, but did not clearly define how to interpret a partial response by mIBG scan (Brodeur et al, 1993).…”

mentioning

confidence: 99%

Criteria for evaluation of disease extent by 123I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force

et al. 2010

View full text Add to dashboard Cite

BACKGROUND: Neuroblastoma is an embryonic tumour of the sympathetic nervous system, metastatic in half of the patients at diagnosis, with a high preponderance of osteomedullary disease, making accurate evaluation of metastatic sites and response to therapy challenging. Metaiodobenzylguanidine (mIBG), taken into cells via the norepinephrine transporter, provides a sensitive and specific method of assessing tumour in both soft tissue and bone sites. The goal of this report was to develop consensus guidelines for the use of mIBG scans in staging, response assessment and surveillance in neuroblastoma. METHODS: The International Neuroblastoma Risk Group (INRG) Task Force, including a multidisciplinary group in paediatric oncology of North and South America, Europe, Oceania and Asia, formed a subcommittee on metastatic disease evaluation, including expert nuclear medicine physicians and oncologists, who developed these guidelines based on their experience and the medical literature, with approval by the larger INRG Task Force. RESULTS: Guidelines for patient preparation, radiotracer administration, techniques of scanning including timing, energy, specific views, and use of single photon emission computed tomography are included. Optimal timing of scans in relation to therapy and for surveillance is reviewed. Validated semi-quantitative scoring methods in current use are reviewed, with recommendations for use in prognosis and response evaluation. CONCLUSIONS: Metaiodobenzylguanidine scans are the most sensitive and specific method of staging and response evaluation in neuroblastoma, particularly when used with a semi-quantitative scoring method. Use of the optimal techniques for mIBG in staging and response, including a semi-quantitative score, is essential for evaluation of the efficacy of new therapy.

show abstract

Evaluation of semi‐quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma

Cited by 78 publications

References 25 publications

PET/CT and MIBG scans in diagnosis and management of Neuroblastoma

PET/CT and MIBG scans in diagnosis and management of Neuroblastoma

Semi-quantitative scoring of skeletal metastases by 123I-mIBG scintigraphy in high-risk neuroblastoma

Criteria for evaluation of disease extent by 123I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force

Contact Info

Product

Resources

About